NXTC · NextCure, Inc. · Executive Compensation
$4.98
+0.26 (+5.51%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our expectation to incur additional operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$21.61M
Shares
4.58M
Volume · Oct 23
48.55K
Avg daily vol (3M)
189.6K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Richman | President and Chief Executive Officer | $941,692 |
| Udayan Guha | M.D., Ph.D. Chief Medical Officer | $639,239 |
| Timothy Mayer | Chief Operating Officer | $633,181 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Richman | President and Chief Executive Officer | $1,510,939 |
| Solomon Langermann | Chief Scientific Officer | $882,845 |
| Han Myint | M.D., FACP former Chief Medical Officer | $874,322 |
| Timothy Mayer | Ph.D. Chief Operating Officer | $872,206 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Richman | President and Chief Executive Officer | $1,044,627 |
| Han Myint | M.D., FACP former Chief Medical Officer | $697,932 |
| Sol Langerman. Ph.D | Chief Scientific Officer | $681,586 |
| Solomon Langermann | Chief Scientific Officer | $681,586 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Richman | President and Chief Executive Officer | $1,724,186 |
| Sol Langerman. Ph.D | Chief Scientific Officer | $990,524 |
| Sol Langermann | Chief Scientific Officer | $990,524 |
| Han Myint | M.D., FACP Chief Medical Officer | $953,318 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michael Richman | President and Chief Executive Officer | $3,321,425 |
| Han Myint | M.D., FACP Chief Medical Officer | $2,261,982 |
| Sol Langermann | Chief Scientific Officer | $1,392,982 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael Richman | President and Chief Executive Officer | $6,488,396 |
| Kevin Heller | Former Chief Medical Officer | $2,838,459 |
| Sol Langermann | Chief Scientific Officer | $2,484,687 |
| James B. Bingham | Chief Development Officer | $2,447,482 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michael Richman | President and Chief Executive Officer | $625,679 |
| Kevin Heller | Former Chief Medical Officer | $505,294 |
| Sol Langermann | Chief Scientific Officer | $459,105 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael Richman | President and Chief Executive Officer | $2,501,597 |
| Sol Langermann | Chief Scientific Officer | $882,291 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John G. Houston, PH.D. | Class I Director | Appointed | 2026-06-25 |
| Anne Borgman, M.D. | Class I Director | Appointed | 2026-06-25 |
| Solomon Langermann, Ph.D. | Chief Scientific Officer | Resigned | 2025-08-25 |
| Dr. Han Myint, M.D. | Chief Medical Officer | Retired | 2024-06-18 |
| Garry A. Nicholson | board of directors | Resigned | 2023-07-19 |
Leadership
- Michael Richman CEO
- Steven P. Cobourn CFO
- Timothy Mayer COO
- Kevin G. Shaw General Counsel
- Anne Borgman Board Member
- Anne Borgman, M.D. Board Member
- Ellen Feigal Board Member
- John G. Houston, PH.D. Board Member